(Total Views: 652)
Posted On: 10/22/2024 1:03:35 AM
Post# of 148865
Dr Max Lataillade
Bristol-Myers Squibb Pharmaceuticals
2014 presentation.
Funded by BMS.
AI438011:
A Phase IIb, Randomized, Controlled, Partially-Blinded Trial to Investigate the Safety,
Efficacy and Dose-response of BMS-663068 in Treatment-Experienced HIV-1-positive Subjects
Prodrug metabolized to BMS-626529, a first-in-class
attachment inhibitor that binds to HIV-1 gp120, preventing initial viral attachment and entry into
the host CD4+ T cell1,2
Author Affiliations:
*Jacob Lalezari, Quest Clinical
Research, San Francisco, CA, USA
Gulam H Latiff, Maxwell Clinic, Durban, South Africa
Cynthia Brinson, Central Texas Clinical Research, Austin, TX, USA
Juan Echevarría, Hospital Nacional Cayetano Heredia, Lima, Peru
Sandra Treviño-Pérez, Mexico Centre for Clinical Research, Mexico City, Mexico
Johannes Bogner, Hospital of the University of Munich, Munich, Germany
*Max Lataillade,
Samit R Joshi, David Stock, Bristol-Myers Squibb, Wallingford, CT, USA
George J Hanna, Bristol-Myers Squibb, Princeton, NJ, USA
____
This other 2020 trial publication:
Max Lataillade et al. Lancet HIV. 2020 Nov
Findings:
"Between Feb 23, 2015, and Aug 11, 2016, 371 participants were enrolled....."
Methods: BRIGHTE (NCT02362503) is an ongoing multicentre, two-cohort, phase 3 trial, done at 108 centres in 22 countries.
* Notice funded by ViiV
* Click on the actual trial link.
Says 138 locations
* Notice all 138 are all GSK
https://clinicaltrials.gov/study/NCT02362503
Remember, during covid, we felt like BP took all trial sites.
Well, our new friend, Dr. Lataillade has access(ed) to @ minimum 138 GSK Investigational Sites.
Guessing being Investigational Sites is flexible to trialing far beyond HIV.
What is Dr. Lataillade responsibilities again?
" Dr. Lataillade will lead the Company’s global research and development strategy and oversee end-to-end R&D activities to advance the Company’s clinical development pipeline."
Dr. Lataillade matching LL indications beyond HIV, to GSK sites?
Sure's seems to make sense now.
If so, imagine how smooth LL trials would proceed, with no black box for the doctors & staff.
Who knows the end-game, but it sure sounds like a future, internal ecosystem of support is very possible.
I'm just sayin....
: )
Bristol-Myers Squibb Pharmaceuticals
2014 presentation.
Funded by BMS.
AI438011:
A Phase IIb, Randomized, Controlled, Partially-Blinded Trial to Investigate the Safety,
Efficacy and Dose-response of BMS-663068 in Treatment-Experienced HIV-1-positive Subjects
Prodrug metabolized to BMS-626529, a first-in-class
attachment inhibitor that binds to HIV-1 gp120, preventing initial viral attachment and entry into
the host CD4+ T cell1,2
Author Affiliations:
*Jacob Lalezari, Quest Clinical
Research, San Francisco, CA, USA
Gulam H Latiff, Maxwell Clinic, Durban, South Africa
Cynthia Brinson, Central Texas Clinical Research, Austin, TX, USA
Juan Echevarría, Hospital Nacional Cayetano Heredia, Lima, Peru
Sandra Treviño-Pérez, Mexico Centre for Clinical Research, Mexico City, Mexico
Johannes Bogner, Hospital of the University of Munich, Munich, Germany
*Max Lataillade,
Samit R Joshi, David Stock, Bristol-Myers Squibb, Wallingford, CT, USA
George J Hanna, Bristol-Myers Squibb, Princeton, NJ, USA
____
This other 2020 trial publication:
Max Lataillade et al. Lancet HIV. 2020 Nov
Findings:
"Between Feb 23, 2015, and Aug 11, 2016, 371 participants were enrolled....."
Methods: BRIGHTE (NCT02362503) is an ongoing multicentre, two-cohort, phase 3 trial, done at 108 centres in 22 countries.
* Notice funded by ViiV
* Click on the actual trial link.
Says 138 locations
* Notice all 138 are all GSK
https://clinicaltrials.gov/study/NCT02362503
Remember, during covid, we felt like BP took all trial sites.
Well, our new friend, Dr. Lataillade has access(ed) to @ minimum 138 GSK Investigational Sites.
Guessing being Investigational Sites is flexible to trialing far beyond HIV.
What is Dr. Lataillade responsibilities again?
" Dr. Lataillade will lead the Company’s global research and development strategy and oversee end-to-end R&D activities to advance the Company’s clinical development pipeline."
Dr. Lataillade matching LL indications beyond HIV, to GSK sites?
Sure's seems to make sense now.
If so, imagine how smooth LL trials would proceed, with no black box for the doctors & staff.
Who knows the end-game, but it sure sounds like a future, internal ecosystem of support is very possible.
I'm just sayin....
: )
(12)
(0)Scroll down for more posts ▼
